A Phase 2 interventional study of GDC-0853 in Urticaria, sponsored by Genentech, Inc.. Terminated at 10 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Urticaria with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Urticaria · United States.
Among the 47 studies in Urticaria with a site in United States, this one is the 21st largest by enrollment of the 37 interventional ones that give a count, is the only one that started in 2018, is one of 16 in phase 2, and was the 31st registered.
148 studies on the registry are indexed under Urticaria; 20 are open to participants now.
Browse Urticaria studies →4 of the 47 studies in Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Pfizer · Sites in United States, Bulgaria, Canada and 7 more countries
Ages 18+
Foundation For Rare Disease Research · Sites in United States
Ages 12–75 · Healthy volunteers
Columbia University · Sites in United States
Ages up to 99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 6 · Phase 4 3
First in 1976; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 51 across 104 interventional studies indexed under Urticaria.
Median enrollment 39 across the 37 interventional studies, 83 across the 10 observational. Of the 39 that completed or were terminated, 21 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
Hoffmann-La Roche has 4 studies filed under Urticaria — fewer than ten, so there is no comparison to draw.
3 of the studies in Urticaria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT06210698Foundation For Rare Disease ResearchAngioedema Biomarker Research Study | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies in Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, multicenter, open-label extension (OLE) study to evaluate the long-term safety and efficacy of fenebrutinib in participants with Chronic Spontaneous Urticaria (CSU) who have completed the treatment period in a fenebrutinib CSU parent study. Participants may enroll in this OLE study at any time after completing the treatment period of the parent study. Participants will receive open-label fenebrutinib at a dose of 200 milligram (mg) orally twice a day. Treatment may continue until the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
Drug: GDC-0853
Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
Drug: GDC-0853
Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
Also known as: fenebrutinib, RO7010939
Percentage of Participants With Adverse Events (AEs)
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
Time frame: Baseline up until 4 weeks after the last dose of study drug (up to 10 months).
Plasma Concentrations of Fenebrutinib (GDC-0853) at Specified Timepoints
Plasma Concentration Data for fenebrutinib (GDC-0853) will be tabulated and summarised by visits. Descriptive summary statistics for Arithmetic Mean and Standard Deviation will be presented.
Time frame: Week 1 Day 1; Weeks 12 and 24; Study Completion/Early Discontinuation
The study was conducted at 9 centers in 1 country.
| Milestone | Parent Study: GDC-0853 | Parent Study: Placebo |
|---|---|---|
| Started | 23 | 8 |
| Completed | 0 | 0 |
| Not completed | 23 | 8 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Study terminated by sponsor | 20 | 7 |
| Withdrew: Withdrawal by subject | 1 | 1 |
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
| Percentage of Participants | Parent Study: GDC-0853 | Parent Study: Placebo |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 60.9 | 62.5 |
Plasma Concentration Data for fenebrutinib (GDC-0853) will be tabulated and summarised by visits. Descriptive summary statistics for Arithmetic Mean and Standard Deviation will be presented.
| ng/mL | Parent Study: GDC-0853 | Parent Study: Placebo |
|---|---|---|
| Week 1 Day 1 | NA ± NA | NA ± NA |
| Week 12 | 192 ± 181 | 190 ± 278 |
| Week 24 | 130 ± 63.8 | 467 ± 480 |
| Study Completion/Early Discontinuation | NA ± NA | NA ± NA |
Collected over Baseline up until 4 weeks after the last dose of study drug (up to 10 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Parent Study: GDC-0853 | 0/23 (0%) | 0/23 (0%) | 4/23 (17.4%) |
| Parent Study: Placebo | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Event | Parent Study: GDC-0853 | Parent Study: Placebo |
|---|---|---|
| INCREASED TENDENCY TO BRUISEBlood and lymphatic system disorders | 0/23 | 1/8 |
| DIARRHOEAGastrointestinal disorders | 0/23 | 1/8 |
| DYSPEPSIAGastrointestinal disorders | 0/23 | 1/8 |
| GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders | 0/23 | 1/8 |
| ABSCESS LIMBInfections and infestations | 0/23 | 1/8 |
| ORAL HERPESInfections and infestations | 0/23 | 1/8 |
| SKIN INFECTIONInfections and infestations | 0/23 | 1/8 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/23 | 1/8 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 1/23 | 1/8 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 1/23 | 1/8 |
| Age, Continuous(Years) | Parent Study: GDC-0853 | Parent Study: Placebo | Total |
|---|---|---|---|
| Mean | 45.7 ± 16.5 | 40.8 ± 11.0 | 44.5 ± 15.3 |
| Sex: Female, Male(Participants) | Parent Study: GDC-0853 | Parent Study: Placebo | Total |
|---|---|---|---|
| Female | 19 | 6 | 25 |
| Male | 4 | 2 | 6 |
| Race/Ethnicity, Customized(Participants) | Parent Study: GDC-0853 | Parent Study: Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 19 | 3 | 22 |
| Unknown | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Parent Study: GDC-0853 | Parent Study: Placebo | Total |
|---|---|---|---|
| Asian | 1 | 1 | 2 |
| Black or African American | 2 | 1 | 3 |
| White | 20 | 6 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Sep 2018 to primary completion in Oct 2019, 12 months.
Results were first posted in Sep 2020, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenebrutinib